Relevant bibliographies by topics / Carcinomi renali

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Carcinomi renali'

Author: Grafiati
Published: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Carcinomi renali.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Carcinomi renali"

1

Lopez, Chiara, Martina Bollati, Mirko Parasiliti-Caprino, Nunzia Prencipe, Alessandro Maria Berton, Ezio Ghigo, Silvia Grottoli, and Mauro Maccario. "Le neoplasie associate a feocromocitoma/paraganglioma in quadri SDHx positivi o negativi: adenomi ipofisari, tumori stromali gastro-intestinali e tumori renali." L'Endocrinologo 22, no. 4 (August 2021): 330–36. http://dx.doi.org/10.1007/s40619-021-00928-y.

Full text
Abstract:
SommarioI feocromocitomi e paragangliomi (PPGL) sono geneticamente determinati in almeno il 30% dei casi. Le mutazioni identificate più recentemente, in particolare quelle dei geni SDHx, possono favorire, seppur raramente, anche l’insorgenza di tumori stromali gastro-intestinali, carcinomi renali e adenomi ipofisari. Pertanto, in caso di diagnosi di una delle suddette neoplasie, il clinico dovrebbe valutare l’anamnesi personale e familiare alla ricerca di eventuali PPGL, così come in pazienti con PPGL associato a mutazione di SDHx, TMEM127 e MAX si dovrebbe indagare la presenza di neoplasie potenzialmente correlate.
APA, Harvard, Vancouver, ISO, and other styles
2

Matrana, Marc Ryan, Priya Rao, Bradley J. Atkinson, Charles Guo, and Nizar M. Tannir. "Therapies and outcomes of non-renal cell carcinoma (non-RCC) neoplasms of the kidney: A single-institution experience." Journal of Clinical Oncology 30, no. 5_suppl (February 10, 2012): 431. http://dx.doi.org/10.1200/jco.2012.30.5_suppl.431.

Full text
Abstract:
431 Background: Non-RCC neoplasms of the kidney include neuroendocrine tumors (small cell carcinoma and carcinoid) and Primitive Neuroectodermal Tumors (PNET). Small cell carcinoma and renal carcinoids are small blue cell tumors that rarely occur as primary renal neoplasms. PNET, known as extraskeletal Ewing sarcoma, is characterized by t(11;22), the gold standard for diagnosis. It is a small round cell tumor derived from the neural crest and treated with chemotherapy; the role of nephrectomy is unclear. Methods: We reviewed records of patients seen at MDACC between 01/01/2001 and 01/01/2011 for PNET, small cell carcinomas, and carcinoid tumors of the kidney. Overall survival (OS) was determined from diagnosis to death. Results: 21 pts met inclusion criteria. Disease-specific data is shown in the table. Common treatments included: carboplatin/etoposide for small cell carcinomas; vincristine/doxorubicin/ifosfamide, vincristine/doxorubicin/cyclophosphamide, and doxorubicin/ifosfamide alternating with cisplatin/etoposide for PNET. Irinotecan was a common salvage agent in PNET. Most carcinoid tumors were treated with surgery alone. Two patients with small cell received whole brain radiation for brain metastases. Conclusions: Carcinoid tumors of the kidney had better outcomes compared to renal small cell carcinomas or PNET. Local carcinoid tumors of the kidney were generally managed with surgery alone. Renal small cell carcinomas and PNET were treated with systemic therapies. [Table: see text]
APA, Harvard, Vancouver, ISO, and other styles
3

Liddell, Heath, Anton Mare, Sean Heywood, Genevieve Bennett, and Hin Fan Chan. "Clear Cell Papillary Renal Cell Carcinoma: A Potential Mimic of Conventional Clear Cell Renal Carcinoma on Core Biopsy." Case Reports in Urology 2015 (2015): 1–4. http://dx.doi.org/10.1155/2015/423908.

Full text
Abstract:
Clear cell papillary renal cell carcinoma (CCP-RCC) is a recently described, relatively uncommon variant of renal cell carcinoma (RCC) with a reported incidence of 4.1%. Thought to only arise in those with end stage renal disease, CCP-RCC is increasingly identified in those without renal impairment. CCP-RCCs have unique morphologic, genetic, and immunohistochemical features distinguishing them from both conventional clear cell renal cell carcinomas and papillary renal cell carcinomas. Immunohistochemically, these tumors are positive for CK7 and negative for CD10 and racemase. This is in contrast to conventional cell renal cell carcinomas (CK7 negative, CD10 positive) and papillary cell carcinomas (CK7, CD10, and racemase positive). These tumours appear to be indolent in nature, with no current documented cases of metastatic spread. We present the case of a 42-year-old female who presented with an incidental finding of a renal mass that on a core biopsy was reported as clear cell carcinoma, Fuhrman grade 1. She subsequently underwent a radical nephrectomy and further histological examination revealed the tumor to be a clear cell papillary renal cell carcinoma, Fuhrman grade 1.
APA, Harvard, Vancouver, ISO, and other styles
4

Cheng, Shaun Kian Hong, and Khoon Leong Chuah. "Metastatic Renal Cell Carcinoma to the Pancreas: A Review." Archives of Pathology & Laboratory Medicine 140, no. 6 (June 1, 2016): 598–602. http://dx.doi.org/10.5858/arpa.2015-0135-rs.

Full text
Abstract:
The pancreas is an unusual site for tumor metastasis, accounting for only 2% to 5% of all malignancies affecting the pancreas. The more common metastases affecting the pancreas include renal cell carcinomas, melanomas, colorectal carcinomas, breast carcinomas, and sarcomas. Although pancreatic involvement by nonrenal malignancies indicates widespread systemic disease, metastatic renal cell carcinoma to the pancreas often represents an isolated event and is thus amenable to surgical resection, which is associated with long-term survival. As such, it is important to accurately diagnose pancreatic involvement by metastatic renal cell carcinoma on histology, especially given that renal cell carcinoma metastasis may manifest more than a decade after its initial presentation and diagnosis. In this review, we discuss the clinicopathologic findings of isolated renal cell carcinoma metastases of the pancreas, with special emphasis on separating metastatic renal cell carcinoma and its various differential diagnoses in the pancreas.
APA, Harvard, Vancouver, ISO, and other styles
5

Nikumbh, Dhiraj B. "Collecting duct carcinoma (Bellini Duct Carcinoma) of kidney-An overview." IP Archives of Cytology and Histopathology Research 7, no. 4 (November 15, 2022): 211–13. http://dx.doi.org/10.18231/j.achr.2022.048.

Full text
Abstract:
Renal cell carcinoma (RCC) accounts for more than eighty-five percent of primary renal cell carcinomas with male preponderance in 5 to 7 decades. Collecting duct carcinoma (CDC) constitutes for less than 1% of all renal cell carcinomas. Histopathological examination of all types of RCC is almost importance in view of therapeutic and prognostic implications of its varied subtypes. The purpose of this editorial is to highlight the morphology and rarity of collecting duct carcinoma and differentiation of it from papillary renal cell carcinoma.
APA, Harvard, Vancouver, ISO, and other styles
6

Young, Allison, and Lakshmi P. Kunju. "High-Grade Carcinomas Involving the Renal Sinus: Report of a Case and Review of the Differential Diagnosis and Immunohistochemical Expression." Archives of Pathology & Laboratory Medicine 136, no. 8 (August 1, 2012): 907–10. http://dx.doi.org/10.5858/arpa.2012-0196-cr.

Full text
Abstract:
We report the case of a high-grade carcinoma involving the kidney in a young male with renal vein thrombosis and review the differential diagnosis and immunohistochemical workup. High-grade neoplasms involving the renal sinus include collecting duct carcinomas (CDCs), renal medullary carcinomas (RMCs), invasive high-grade urothelial carcinoma (UC) of the upper urinary tract, clear cell renal cell carcinoma, and type 2 papillary renal cell carcinoma. Distinguishing UC from CDC and RMC is problematic in small biopsy samples. The diagnosis of CDC (a rare, aggressive subtype of renal cell carcinoma) is challenging and requires the exclusion of UC. Renal medullary carcinoma is characterized by an appropriate clinical setting and consistent loss of nuclear expression of integrase interactor 1 (INI-1). A panel consisting of p63, paired box gene 8 (PAX8), and INI-1 is most optimal in distinguishing UC from CDC and RMC. A subset of urothelial carcinoma of upper urinary tract may be positive with PAX8.
APA, Harvard, Vancouver, ISO, and other styles
7

Baranovska, V. V., A. M. Romanenko, and L. M. Zakhartseva. "HISTOLOGICAL FEATURES OF CHROMOPHOBE RENAL CELL CARCINOMA." Eastern Ukrainian Medical Journal 8, no. 1 (2020): 15–23. http://dx.doi.org/10.21272/eumj.2020;8(1):15-23.

Full text
Abstract:
Introduction. Renal neoplasms are a common disease. Differential diagnostics of different tumor subtypes for prognosis and treatment is necessary given that some of them, like renal cell oncocytomas, are benign, and others, like chromophobe renal cell carcinomas, are malignant. Unfortunately, the histological similarity between these tumors makes accurate diagnostics difficult. In some cases, additional diagnostic methods such as immunohistochemistry should be used. The aim of our study is to analyze the histological characteristics of chromophobe renal cell carcinomas and renal oncocytomas, in order to specify their pathognomonic features, allowing for the confirmation of the diagnosis. Materials and methods. We used data from histories of disease and histological postoperative material of 198 patients with chromophobe renal cell carcinoma and renal oncocytoma. After the diagnosis was confirmed, we described the histological features of the tumors and calculated their relative prevalence amongst the renal oncocytoma and chromophobe renal cell carcinoma tissues. To conclude, we identified the histological features that are more likely to be present in the case of chromophobe renal cell carcinoma. Conclusions. Chromophobe renal cell carcinomas are present in 31 % of our samples. Tumors are more prevalent in patients in their sixth and seventh decade. Most chromophobe renal cell carcinomas are unilateral. Chromophobe renal cell carcinomas have a polymorphic histological structure. The classic variant of chromophobe renal cell carcinoma is more common than the eosinophilic one. A mixed variant of chromophobe renal cell carcinoma is present in a minority of cases. The most common features of ChRCC are solid and alveolar growth patterns, clear and reticular cytoplasm, raisinoid nuclei. After comparing the relative prevalence of various histological features in renal oncocytomas to those present in chromophobe renal cell carcinomas, we are able to ascertain that chromophobe renal cell carcinomas tend to exhibit the following features significantly more often than renal oncocytomas: differing nuclear size, raisinoid nuclei, reticular cytoplasm, clear cytoplasm. The particular features mentioned in the preceding paragraph, can be present on a small subset of the tumor tissue, and are thus, often missed during analysis, which can lead to misdiagnosis. In order to mitigate this risk, we recommend analyzing a big sample of tumor tissue and using additive methods such as immunohistochemistry with biomarkers CD 10 (56C6), CD 68 (KP1), Cytokeratin 7 (OV-TL 12/30), CD117/c-kit, Vimentin (Vim3B4), S-100 (4C4.9).
APA, Harvard, Vancouver, ISO, and other styles
8

Korkes, Fernando, Luiz Renato Montez Guidoni, Alvaro Alexandre Dias Bosco, Roni de Carvalho Fernandes, Marília Germanos de Castro, Moacyr Fucs, and Marjo Deninson Cardenuto Perez. "CARCINOMA DE CÉLULAS RENAIS EM RIM TRANSPLANTADO: RELATO DE CASO E REVISÃO DA LITERATURA." Brazilian Journal of Transplantation 8, no. 3 (June 1, 2005): 401–3. http://dx.doi.org/10.53855/bjt.v8i3.391.

Full text
Abstract:
Introdução e objetivo: A doença renal cística adquirida tem sido relatada em rins de pacientes com doença renal terminal sem tratamento, tratados com diálise ou que foram submetidos a transplante renal. A incidência de tumor renal em pacientes com doença renal cística adquirida submetidos à diálise é elevada. Recentemente, foram relatados casos de carcinoma de células renais ocorrendo nos rins primitivos com doença renal cística adquirida de pacientes submetidos a transplante. O presente relato tem como objetivo descrever mais um caso de carcinoma renal em enxerto renal. Método e Relato do Caso: Relatamos um caso de carcinoma de células renais ocorrendo após 14 anos (169 meses) de transplante de doador vivo, no aloenxerto com doença renal cística adquirida, após ter evoluído com rejeição, tendo sido tratado com sucesso com a nefrectomia do enxerto. Conclusões: Pacientes submetidos a transplantes têm maior incidência de malignidade, quando comparados com a população geral. Incluindo este relato, são descritos 24 casos de neoplasias renais de novo em aloenxertos renais e, até onde vai nosso conhecimento, é o terceiro caso de carcinoma de células renais associado a doença renal cística adquirida em aloenxerto renal, e o primeiro da literatura nacional.
APA, Harvard, Vancouver, ISO, and other styles
9

Andrabi, Syed Aadil Shadaab, and Syed Mushtaq Ahmad Shah. "Bilateral renal cell carcinoma operated as right radical nephrectomy and left partial nephrectomy with histopathologically confirmed R0 resection." International Surgery Journal 7, no. 6 (May 26, 2020): 2043. http://dx.doi.org/10.18203/2349-2902.isj20202431.

Full text
Abstract:
Bilateral renal tumors remain relatively uncommon, accounting for 1-5% of patients with renal cell carcinoma. Most sporadic renal cell carcinomas are unilateral and unifocal. Bilateral involvement can be synchronous or asynchronous and is found in 2-4% of sporadic renal cell carcinomas. We report a case of 70 years old male who was incidentally found to have bilateral renal masses. Right sided radical nephrectomy and left partial nephrectomy was performed. Histopathological examination of the specimen revealed clear cell carcinoma and confirmed R0 resection. The patient was discharged on 7th postoperative day.
APA, Harvard, Vancouver, ISO, and other styles
10

Lindgren, Valerie, Gladell P. Paner, Robert C. Flanigan, Joseph I. Clark, Steven C. Campbell, and Maria M. Picken. "Renal Tumor With Overlapping Distal Nephron Morphology and Karyotype." Archives of Pathology & Laboratory Medicine 128, no. 11 (November 1, 2004): 1274–78. http://dx.doi.org/10.5858/2004-128-1274-rtwodn.

Full text
Abstract:
Abstract Although most renal epithelial tumors are derived from the proximal nephron, approximately 10% are believed to originate in the distal nephron. This latter group encompasses oncocytoma, chromophobe renal cell carcinoma, and several rare types, including collecting duct carcinoma and renal medullary carcinoma. Despite progress in the classification of renal tumors, a small subset of renal carcinomas remains unclassified (ie, renal cell carcinoma, not otherwise specified). We describe a metastatic tumor consisting of cells with overlapping distal nephron morphologies, including foci of oncocytoma, chromophobe renal cell carcinoma, and collecting duct carcinoma, as well as sarcomatoid dedifferentiation. Special stains were inconclusive, and ultrastructural study demonstrated abundant mitochondria and no microvesicles. The karyotype was hypodiploid with 41 chromosomes and abnormalities reported in all 3 phenotypes present. Rearrangements of 1p and of 11q13 previously seen in divergent subsets of oncocytomas were concomitantly present in the current tumor. Thus, this malignancy has features consistent with distal nephron derivation and demonstrates the convergence of the varied tumor morphologies arising within this site. Furthermore, this case exemplifies the value of cytogenetic analysis in the characterization of renal cell carcinoma, not otherwise specified. In view of recent advances in treatment approach, especially for collecting duct carcinoma, further categorization of this nondescript and heterogeneous group of renal cell carcinomas, not otherwise specified, at least by its derivation in relationship to the renal nephron (distal vs proximal), may be of value in the choice of treatment modality.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Carcinomi renali"

1

Tiroli, Marco. "Fattori prognostici nei carcinomi renali non a cellule chiare. Nostra esperienza." Doctoral thesis, Università Politecnica delle Marche, 2013. http://hdl.handle.net/11566/242681.

Full text
Abstract:
Introduzione: Il carcinoma renale a cellule chiare (ccRCC) è l’istotipo più frequente di tumore renale (circa l’ 80% di tutti). Ciononostante vi sono anche istotipi meno frequenti. Il carcinoma renale papillare (pRCC) rappresenta il secondo istotipo per frequenza, nondimeno finora solo pochi lavori hanno analizzato il suo comportamento in studi osservazionali a lungo termine, con casistiche consistenti. In questo lavoro sono stati considerati tutti i casi di pRCC operati dal 1997 al 2011 presso il nostro centro. I pazienti sono stati seguiti fino a Dicembre 2012, stratificandoli sulla base delle condizioni pre-operatorie e sui parametri pre-operatori, considerando le variabili dei nomogrammi in uso sia per le forme a cellule chiare che per tutte le istologie, valutando la consistenza di tali nomogrammi per l’istologia papillare. Pazienti e metodi: Sono stati individuati 468 pazienti, operati dal 1997 al 2011 per neoformazioni renali. Fra questi, 60 sono stati selezionati, identificati come pRCC. Le caratteristiche cliniche e parametri patologici sono stati raccolti dai referti di laboratorio, anatomopatologici e dal’imaging strumentale: età, genere, dimensioni ed estensione del tumore, tipo di chirurgia, invasione capsulare, del tessuto adiposo, linfonodale; parametri laboratoristici: leucociti, neutrofili e linfociti, emoglobina, LDH, sodiemia, potassiemia, calcemia. Sono stati testati i nomogrammi disponibili, per valutare la loro validità ed estendibilità all’istotipo papillare. Il tempo alla recidiva/progressione è stato scelto come variabile di outcome. E’ stata eseguita analisi della sopravvivenza con metodo di Kaplan-Meier e regressione di Cox sulla coorte di studio. I risultati sono stati confrontati con i dati in letteratura. Risultati:Fra tutte le variabili esaminate, solo lo stadio T (raggruppato) e l’invasione del grasso ilare sono risultati significativi all’analisi univariata, mantenendo tale significatività al modello multivariabile. Fra i nomogrammi, solo lo scoring di Karakiewicz ha dimostrato ruolo quale predittore indipendente. Nessun parametro laboratoristico ha dimostrato un ruolo come variabile predittiva. Discussione e Conclusioni: Nonostante le dimensioni della coorte, questa può essere considerata al di sopra della media degli studi finora condotti. Solo un gruppo limitato di parametri pre- o intraoperatori si è dimostrato valido come predittore di tempo alla recidiva per il pRCC, sia autonomamente che quale variabile all’interno di nomogrammi. Per lo staging, comunque, solo un raggruppamento di più stadi è risultato significativo, a suggerire la necessità di rivedere l’attuale classificazione in relazione ai differenti istotipi. Sarebbe comunque raccomandabile l’esecuzione di studi multicentrici con casistiche più ampie, per definire meglio i caratteri di questa patologia.
Introduction: Clear cell histology (ccRCC) represents the most common subtype of renal cell carcinoma, accounting for almost 80% of all renal malignancies. Nevertheless, other less common entities can be met during surgical removal of renal masses. Papillary renal cell carcinoma (pRCC) is the second most common histology, nevertheless only few works investigated its behavior in long-time observations with consistent case series. In this work all cases of pRCC operated from 1997 to 2011 at our clinic were collected. Surgical and clinical outcome were followed-up until December 2012, matched with pre-operative patients’ conditions and with laboratory parameters already considered in survival nomograms currently in use for clear cells type, in order to test the consistency of the results for a different histology. Patients and methods: 468 patients were collected, operated at our center from 1997 to 2011 for renal masses. Among these, 60 were selected, by whom a papillary histology resulted at the pathological examination. Clinical and laboratory pre-operative features were collected from patients clinical reports and histological and surgical features collected from pathological reports and imaging diagnostics: age at intervention, gender, tumor dimensions, tumor extension, type of surgery, fat invasion, lymph nodes invasion; laboratory parameters: leucocytes, neutrophils and lymphocytes count, hemoglobin, LDH, sodium, potassium, calcium. Currently available nomograms for different histological subtypes were tested to assess their validity on pRCC. Time to progression/recurrence was chosen as outcome variable. Survival analysis with Kaplan-Meier method and Cox-regression analysis were performed on the whole cohort of cases and the results were compared with the data obtained from the literature. Results: Of all variables tested, only cumulative T-staging and hilar fat invasion were significant at univariate analysis, keeping their significance as independent predictors at the multivariable model, while only Karakiewicz score resulted as independent significant variable among the different models tested. No role could be determined for any of the pre-operative laboratory parameters tested in our series. Discussion and Conclusions: Despite the small dimensions of our cohort study, it can be considered over the average of the studies so far performed on this pathology. Only a limited group of pre- /intra-operative parameters usually considered when considering ccRCC, as themsevews or within predictive nomograms could find a role as predicting parameters for pRCC. For staging parameters, only grouped variables were significant, suggesting that a revision in the classification should be considered, according to the different subtypes. Anyway, further studies considering wider case series, even from multicentric groups would be advisable.
APA, Harvard, Vancouver, ISO, and other styles
2

MOROSI, LAVINIA. "Studi di proteomica subcellulare nelle patologie renali: carcinoma renale e nefropatia diabetica." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2012. http://hdl.handle.net/10281/28933.

Full text
Abstract:
ABSTRACT Renal cell carcinoma (RCC) is among the 10 leading causes of cancer-related deaths worldwide and its incidence is increasing steadily. At the time of diagnosis, 30% of patients have metastases and another third will develop metastatic disease within 10 years. Moreover metastatic RCC is radio- and chemotherapy resistant. Diabetic nephropathy (DN) is a common diabetic complication that causes a renal massive functional deficit making dialysis or transplantation essential for the survival of patients and it is associated with alterations in the expression of several renal proteins. Therefore, it is important to identify differentially expressed proteins to be used as potential diagnostic and/or prognostic markers in RCC and DN. A promising strategy is comparative subcellular proteomics of urinary exosomes, membranous vesicles released from cells and membrane microdomains, lipid arfts and caveolae. About 30 ml of urines were collected from 29 clear cell RCC patients and 28 healthy matched controls and stored at -80°C, after antiproteases addition. Diabetes was induced in 10 Sprague Dawley rats by streptozotocin injection. Control rats (n=4) underwent only buffer injection. Out of 10 diabetic rats, 4 were chronically treated with insulin. After 3 months, 24 hours urines were collected. In both cases (RCC patients and diabetic rats with their healthy controls respectively) exosomes were then isolated from total urines by ultracentrifugation after cells and debris clearing. As regards RCC esults show that the protein profile of urinary exosomes is peculiar: the most abundant urinary proteins of plasmatic origin (i.e. albumin) are markedly reduced, while the Tamm Horsfall protein (THP) is highly enriched and affected by a significant biological variability. Moreover, protein profiles of exosomal fractions isolated from urine of ccRCC and matched controls show some difference. Mass spectrometry analysis of two pools of exosomes isolated from CTRL and RCC patients urines permits the identification of 261 proteins in CTRL and 187 proteins in RCC. Some of these protein Aquaporin-1, Matrix Metallo-protease 9 and Carbonic Anhydrase 9, display differential amount in ccRCC patient urine exosomes by EF/WB. Moreover subcellular fractions were prepared by differential centrifugation from surgical samples of RCC and adjacent normal kidney (ANK). MD were isolated from plasma-membrane-enriched fractions after treatment with Triton X-100 and sucrose density gradient ultracentrifugation. MD derived from RCC and ANK tissues of 7 patients were pooled, and proteins separated by 4-12% and 12% gel electrophoresis. After Coomassie Blue staining, bands were excised and analyzed by LC-MS/MS after trypsin digestion. We identified 83 proteins from microdomains isolated from RCC tissue, and 95 proteins from ANK. About 60% of the identified proteins are membrane-associated and about half of these resulted microdomain-associated. GRAVY scores assignment shows that most identified proteins (about 70%) are in the hydrophobic range. From a functional point of view, we found proteins involved in signal transduction (Ras related proteins), channels (Aquaporin-1), carriers (P-glycoprotein) and cytoskeleton structural constituents (Spectrin). We chose some promising proteins such as Renal dipeptidase (identified only in ANK MD) or Emmprin (overexpressed in RCC tissue) and investigated their differential expression of by WB About DN study, protein profiles of exosomes obtained from the three groups of rat (healthy controls CTRL, diabetic D and diabetic treated with insulin DI) show differences, mainly at low molecular weights. Some differential bands were excised and analyzed by LC-MS/MS after digestion by tripsin. In particular we identified the Major Urinary Proteins, known as MUPs from CTRL and DI gels, while these proteins are not present in the same bands excised from D gels. MUPs regulate glucose and lipid metabolism suggesting an involvement in hyperglycemia, insulin resistance and/or glucose intolerance in diabetes.
APA, Harvard, Vancouver, ISO, and other styles
3

Reis, Mário Marques de Oliveira. "Carcinoma renal : Estudo anatomoclínico." Doctoral thesis, Universidade do Porto. Reitoria, 1989. http://hdl.handle.net/10216/10169.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Reis, Mário Marques de Oliveira. "Carcinoma renal : Estudo anatomoclínico." Tese, Universidade do Porto. Reitoria, 1989. http://hdl.handle.net/10216/10169.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

BIANCONI, MARISTELLA. "Il profilo angiogenico nel carcinoma renale metastatico: implicazioni prognostiche e terapeutiche." Doctoral thesis, Università Politecnica delle Marche, 2018. http://hdl.handle.net/11566/253118.

Full text
Abstract:
Il trattamento del carcinoma renale avanzato è radicalmente cambiato nell’ultimo decennio. Le opzioni disponibili sono per la maggior parte dirette contro la via dell’angiogenesi. Nonostante questo i pazienti trattati sperimentano outcome molto diversi tra di loro e, al momento, non possediamo fattori predittivi. Sulla scorta delle nostre precedenti analisi dei polimorfismi di VEGF e VEGFR nel carcinoma renale avanzato in pazienti trattati in prima linea con sunitinib o pazopanib, abbiamo voluto analizzare l’eventuale influenza di tali polimorfismi per quanto concerne la seconda linea. Dei pazienti trattati per carcinoma renale avanzato, 63 sono risultati eleggibili per l’analisi in correlazione alla seconda linea. Su questi pazienti sono stati analizzati un gruppo di polimorfismi di VEGF e VEGFR correlandoli con la PFS e la OS, i pazienti sono stati divisi in due gruppi in base al trattamento (anti-VEGF vs anti-mTOR). Il polimorfismo rs2010963 di VEGF A mostra un vantaggio in termini di PFS per il genotipo GG o GC nel gruppo anti-VEGF (7,5 vs 3,3 mesi) e nel gruppo trattato con anti-mTOR (6,3 vs 2,9 mesi) (p<0,0001); questo vantaggio persiste in OS sia nel gruppo trattato con anti-VEGF (26,4 vs 10,8 mesi) sia in quello trattato con anti-mTOR (13,2 vs 3,4 mesi) (p=0,0006). Il polimorfismo di VEGFR-3 rs6877011 si è dimostrato vantaggioso in PFS per il genotipo CC nel gruppo anti-VEGF (7,6 vs 3,2 mesi) e per GG o GC nel gruppo trattato con anti-mTOR (10,3 vs 3,7 mesi) (p=0,0018). Per quanto riguarda la OS la presenza di C evidenzia un vantaggio nel gruppo trattato con anti-VEGF (26,4 vs 3,7 mesi) mentre in quello trattato con anti-mTOR il vantaggio si ha con l’espressione di GG o GC (12,9 vs 8,9 mesi) (p=0,0045). Dalle nostre analisi sembra evidenziarsi un profilo angiogenico con i polimorfismi rs833061, rs2010963, rs699947 e rs6877011 che sia in grado di predire la scelta del farmaco in prima linea e indirizzare la scelta della seconda linea di trattamento.
The treatment of advanced renal cell carcinoma has radically changed in the last decade. The options available are for the most part directed against the angiogenic pathway. Despite this, the treated patients experience very different outcomes and we do not have predictive factors so far. Based on our previous analysis of the polymorphisms of VEGF and VEGFR in advanced renal cell carcinoma in patients treated in the first line with sunitinib or pazopanib, we analyzed the possible influence of these polymorphisms in correlation with the second line. Of patients treated for advanced renal cell carcinoma, 63 were eligible for second-line treatment analysis. On these patients a group of polymorphisms of VEGF and VEGFR were analyzed correlating them with the PFS and the OS, the patients were divided into two groups based on the treatment (anti-VEGF vs anti-mTOR). The rs2010963 polymorphism of VEGF A shows an advantage in terms of PFS for the GG or GC genotype in the anti-VEGF group (7.5 vs 3.3 months) and in the anti-mTOR group (6.3 vs 2.9 months) (p <0.0001); this advantage persists in OS both in the group treated with anti-VEGF (26.4 vs 10.8 months) and in the group treated with anti-mTOR (13.2 vs 3.4 months) (p = 0.0006). The polymorphism of VEGFR-3 rs6877011 was shown to be incremental in PFS for the CC genotype in the anti-VEGF group (7.6 vs 3.2 months) and for GG or GC in the anti-mTOR group (10.3 vs 3 , 7 months) (p = 0.0018). As regards the OS the presence of C allele shows an advantage in the group treated with anti-VEGF (26.4 vs. 3.7 months) while in the one treated with anti-mTOR the advantage is with the expression of GG or GC ( 12.9 vs 8.9 months) (p = 0.0045). From our analysis, an angiogenic profile appears with the polymorphisms rs833061, rs2010963, rs699947 and rs6877011 that is able to predict the choice of the drug in the first line and direct the choice of the second line.
APA, Harvard, Vancouver, ISO, and other styles
6

Lima, Marcela Sampaio. "Expressão de Ciclina D1 em Carcinoma de Células Renais." Universidade de São Paulo, 2013. http://www.teses.usp.br/teses/disponiveis/17/17143/tde-21102013-215129/.

Full text
Abstract:
Carcinoma de Células Renais (CCR) representa uma família de tumores distintos com evolução clínica imprevisível. Uma variedade de moléculas tem sido avaliada como marcadores prognósticos para CCR. Ciclina D1, uma proteína reguladora do ciclo celular, encontra-se superexpressa em vários tumores primários. Nosso objetivo é avaliar sua expressão como marcador prognóstico em CCR. Antes disso, traçamos um perfil clínico e histopatológico da amostra e verificamos sua relação com os fatores prognósticos considerados clássicos pela literatura. 109 espécimes de pacientes diagnosticados com CCR foram obtidos entre 2005 e 2010 no Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto USP e submetidos à análise imunoistoquímica juntamente com 07 amostras de tecido renal normal. A maior parte das características epidemiológicas e clínicas de nossa amostra foi similar àquelas descritas na literatura mundial. Houve predomínio do gênero masculino, da raça branca, com idade próxima a 60 anos, frequência de pacientes assintomáticos em torno de 36% e grande prevalência do CCR de células claras (71,55%). A mortalidade específica da doença foi de 13,76%, sendo o CCR de células claras o tipo mais frequente entre os óbitos e casos metastáticos. Os casos que exibiram má evolução clínica, definida pela ocorrência de metástase e/ou óbito por CCR (22,01%), estiveram associados à presença de sintomas ao diagnóstico, maior tamanho tumoral, grupo de estágio alto (III ou IV), grau nuclear de Fuhrman alto (3 ou 4), presença de necrose e de diferenciação sarcomatóide no tumor, além de outros fatores histológicos desfavoráveis (p < 0,01). Isso indica que as variáveis utilizadas na avaliação de prognóstico em países desenvolvidos podem ser aplicadas aos nossos pacientes. Não houve expressão imunoistoquímica de Ciclina D1 nos casos de tecido renal normal. Observou-se heterogeneidade de marcação nuclear intratumoral no total de casos e menor expressão proteica entre os CCR papilífero e cromófobo. Pacientes com tumores com Ciclina D1baixa (até 30% de células positivas) apresentaram má evolução clínica (p = 0,03), maior tamanho tumoral (p = 0,01), presença de sintomas ao diagnóstico (p = 0,04), grau nuclear alto (p = 0,001), presença de necrose (p = 0,004) e de diferenciação sarcomatóide (p = 0,04) no tumor, além de menor sobrevida sem metástase e/ou óbito por CCR (p = 0,03). Após análise multivariada, a expressão de Ciclina D1 não apresentou valor prognóstico independente para má evolução clínica, embora tenha aumentado levemente a acurácia prognóstica do modelo adotado. Em todas as análises realizadas para o CCR de células claras isoladamente, observamos significância estatística semelhante à do total de casos (CCR). Nosso estudo demonstrou que: a proteína Ciclina D1 encontra-se superexpressa em CCR; os tipos de CCR parecem exibir diferentes padrões de marcação imunoistoquímica da Ciclina D1; alta marcação da proteína (acima de 30% de células positivas) esteve associada à boa evolução clínica e à maioria dos fatores prognósticos favoráveis bem estabelecidos na literatura. Novas investigações são necessárias para descobrir que mecanismos levam a seu acúmulo nas células neoplásicas e quais outros eventos podem estar contribuindo para a progressão da doença.
Renal Cell Carcinoma (RCC) is a family of distinct tumors with unpredictable clinical outcome. A variety of molecules have been evaluated as prognostic markers for RCC. Cyclin D1, a cell cycle regulatory protein, is overexpressed in several primary tumors. Our purpose is to evaluate its expression as a prognostic marker in RCC. Before that, we drew a clinical and histopathological profile of the sample and verified its relationship with prognostic factors regarded as classics in literature. 109 specimens from patients diagnosed with RCC were obtained between 2005 and 2010 at Hospital das Clínicas - Ribeirão Preto School of Medicine USP and submitted to immunohistochemical analysis, along with 07 normal kidney tissue samples. Most epidemiological and clinical characteristics of our sample were similar to those described in the literature. There was a predominance of male, Caucasian, aged about 60 years, the frequency of asymptomatic patients around 36%, and high prevalence of clear cell RCC (71.55%). The disease-specific mortality was 13.76%, being the clear cell RCC the most frequent type among deaths and metastatic cases. Cases that exhibited poor clinical outcome, defined by the occurrence of metastasis and/or death by RCC (22.01%), were related to the presence of symptoms at diagnosis, larger tumor size, high stage group (III or IV), high Fuhrman nuclear grade (3 or 4), presence of necrosis and sarcomatoid differentiation in the tumor and other unfavorable histological factors (p < 0.01). This indicates that the variables used in the assessment of prognosis in developed countries can be applied to our patients. There was no immunohistochemical expression of Cyclin D1 in cases of normal kidney tissue. There was intratumoral heterogeneity in nuclear staining in all cases and lower protein expression among papillary and chromophobe RCC. Patients with Cyclin D1low tumors (up to 30% positive cells) showed poor clinical outcome (p = 0.03), larger tumor size (p = 0.01), presence of symptoms at diagnosis (p = 0.04), high nuclear grade (p = 0.001), presence of necrosis (p = 0.004) and sarcomatoid differentiation (p = 0.04) in the tumor and lower survival without metastasis and/or death by RCC (p = 0.03). After multivariate analysis, the expression of Cyclin D1 showed no independent prognostic value for poor clinical outcome, although it has slightly increased the prognostic accuracy of the model adopted. In all analyzes performed for clear cell RCC alone, we observed statistical significance similar to that of the total cases (RCC). Our study showed that: Cyclin D1 protein is overexpressed in RCC; RCC types seem to exhibit different patterns of immunohistochemical staining for Cyclin D1; high protein expression (over 30% positive cells) was related to good clinical outcome and to most favorable prognostic factors well established in the literature. Further investigations are necessary to reveal which mechanisms lead to its accumulation in neoplastic cells and what other events might be contributing to the progression of the disease.
APA, Harvard, Vancouver, ISO, and other styles
7

Silvestre, Cristina. "Meccanismi di immunosorveglianza nella carcinogensei dei reni affetti da end-stage renal disease." Doctoral thesis, Università degli studi di Padova, 2016. http://hdl.handle.net/11577/3424488.

Full text
Abstract:
Background- Chronic kidney disease (CKD) and replacement therapies (dialysis or transplantation) increase the risk of native kidneys cancer. Acquired multicystic kidney disease in dialysis patients and immunosuppressive therapy in transplant recipients might be relevant factors for the development of renal cancer. International guidelines do not clearly recommend specific screening protocols for these categories of patients, although the early diagnosis could lead to an excellent prognosis. Objectives- To retrospectively analyze the cases of renal neoplasms of the native kidneys in chronic renal failure patients and renal transplant recipients that underwent nephrectomy at the Kidney and Pancreas Transplant Center at Hospital-University of Padua. The histological type of the tumor, grading, stage at diagnosis and prognosis of these patients were evaluated and compared with the data reported in the literature in uremic patients and in the general population. In the prospective phase of the study: the histopathological analysis and the flow cytometry of the kidneys have been addressed to study the expression of costimulatory molecules at the level of renal epithelial cells, to determine their function as non-professional APC (Antigen Presenting Cell). The activation status of intraepitelial lymphocyte population have been evaluated. Methods- From April 2007 to June 2013, 18 patients with chronic kidney disease (CKD) and/or kidney transplant recipients underwent nephrectomy because of renal tumor at the Kidney and Pancreas Transplant Center at Hospital-University of Padua. Were analyzed: the cause of the CKD, the type of replacement therapy, the timing of kidney transplantation, immunosuppressive therapy, the histological type of the tumor, the Fuhrman grade, and patient outcomes. Thereafter, between December 2014 and December 2015, 16 patients (5F/11M). were enrolled in the study. Indications for nephrectomy were: polycystic disease (APKD) 13 patients, suspected malignancy of the native kidney 3 patients, 1 patient underwent trasnsplantectomy of his kidney, performed for the detection of an aneurysm of the renal artery. Histological examination showed: neoplasms 2 cell carcinomas (Furhman Furhman 4 and 2 respectively), 1 papillary carcinoma Results- The average age of the patients at the time of nephrectomy was 53.4 ± 11.2 years. Six patients were receiving dialysis (hemodialysis in 2 and 4 on peritoneal dialysis), while 12 patients had a kidney transplant and 1 had previously pancreas and kidney transplantation. One patient developed 2 bilateral metacronous neoplasia and 1 benign tumor. Histological examination showed 17 cases of malignancy (9 clear cell carcinomas and 8 papillary carcinomas) and 3 benign tumors (2 papillary adenoma and a renal oncocytoma). The stage at diagnosis was: in 16 cases T1, and in 1 case T2. All patients underwent nephrectomy: 12 laparoscopically, 5 with laparotomy and 2 by lombotomic approach. All patients were asymptomatic at diagnosis, which took place during ultrasound performed for other reasons and subsequently confirmed at the CT-scan with contrast and / or MRI. After a mean follow-up of 22 ± 20 months, two patients died of causes unrelated to renal cancer and there were no local or distant recurrence of the tumor, in the absence of adjuvant treatment. The flow cytometry seems to show a greater expression of CD80, HLAABCm, HLAABCr; HLADRm and HLADRr; where HLAABCm and HLADRm represent the average intensity of fluorescence per cell, while HLAABCr and HLADRr represent the percentage of cells that exceed the gate and are therefore classified as positive. The expression of MCHC seems to increase in transplant recipient than in non-transplant patients; probably because immunosuppressive therapy, preventing rejection, leads an inhibition of T cell. Conclusions- The diagnosis of kidney cancer which is carried out within the program of follow-up in kidney transplant patients and screening in uremic patients allows to detect cancer in its early stages, improving outcomes and reducing the need for adjuvant therapy. The expression of costimulatory molecule CD80 in patients with renal carcinoma might suggest an activation of immunosurveillance in the carcinogenesis of the kidney. Further studies are needed to clarify the role of immunosuppressive therapy in the immunosurveillance.
Introduzione- L’insufficienza renale cronica (IRC) e specialmente la terapia sostitutiva (dialisi e trapianto), aumentano il rischio di riscontrare tumori dei reni nativi. I fattori che possono essere implicati sono la malattia renale multicistica acquisita nei dializzati e la terapia immunosoppressiva nei pazienti trapiantati. Nelle linee guida internazionali mancano tuttavia delle chiare indicazioni sulla tipologia di screening a cui sottoporre questi pazienti , benché in caso di diagnosi precoce la prognosi di queste neoplasie possa risultare ottima. Scopo dello studio- nella fase retrospettiva dello studio è stata analizzata la casistica di neoplasie renali dei reni nativi in pazienti affetti da insufficienza renale cronica e in pazienti trapiantati di rene e sottoposti a nefrectomia presso l’U.O.C. Trapianti di Rene e Pancreas dell’Azienda Ospedale-Università di Padova. L’istotipo del tumore, il grading, lo stadio alla diagnosi e la prognosi di questa tipologia di pazienti sono stati valutati e confrontati con i dati riportati in letteratura relativi a pazienti uremici e nella popolazione generale. Nella fase prospettica: l'analisi istopatologica e citofluorimetrica dei reni sono state indirizzate allo studio dell'espressione delle molecole di costimolazione a livello delle cellule epiteliali renali, per determinare la loro funzione di antigen presenting cell non professionali. Sono state inoltre analizzate le sottopopolazioni linfocitarie T residenti ed il loro stato di attivazione. Materiali e metodi: Da Aprile 2007 a Giugno 2013, 18 pazienti affetti da IRC e/o trapiantati di rene sono stati sottoposti a nefrectomia per riscontro di neoplasia renale presso la U.O.C. Trapianti Rene e Pancreas dell’Azienda Ospedale- Università di Padova. Sono stati analizzati: la causa dell’IRC, il tipo di terapia sostitutiva, il timing del trapianto di rene, la terapia immunosoppressiva, l’istotipo della neoplasia, il grado Fuhrman, e l’outcome dei pazienti. Successivamente tra dicembre 2014 e dicembre 2015, sono stati arruolati nello studio 16 pazienti (5F/11M). Le indicazioni all’intervento di nefrectomia sono state malattia policistica dell’adulto (APKD) 13 pazienti, sospetta neoplasia del rene nativo 3 pazienti, 1 paziente è stata sottoposta ed espianto di autotrapianto di rene, effettuato per il riscontro di un’aneurisma dell’arteria renale primitiva. Sono state riscontrate le seguenti neoplasie renali 2 carcinomi a cellule chiare (Furhman 4 e Furhman 2 rispettivamente), 1 carcinoma papillare. Risultati- L’età media dei pazienti al momento della nefrectomia era 53.4±11.2 anni. Sei pazienti erano in trattamento dialitico (2 in emodialisi e 4 in dialisi peritoneale), mentre 11 pazienti erano trapiantati di rene e 1 era trapiantato di pancreas e rene. Un paziente ha presentato due neoplasie maligne bilaterali metacrone ed un tumore benigno. L’esame istologico ha evidenziato 17 casi di neoplasia maligna (9 carcinomi a cellule chiare e 8 carcinomi papillari) e 3 di tumore benigno (due adenomi papillari e un oncocitoma renale). Lo stadio alla diagnosi era: in 16 casi T1 ed in un caso T2. Tutti i pazienti sono stati sottoposti a nefrectomia: 12 per via laparoscopica, 5 per via laparotomica e 2 per via lombotomica. Tutti i pazienti erano asintomatici alla diagnosi, che è avvenuta in corso di ecografia eseguita per altre ragioni e successivamente confermata all’esame TAC con mezzo di contrasto e/o RM. Dopo un follow-up medio di 22±20 mesi, due pazienti sono deceduti per cause non collegate alla neoplasia renale e non si sono verificate recidive locali o a distanza della neoplasia, in assenza di trattamento adiuvante. L’analisi puramente descrittiva della citofluorimetria sembra evidenziare una maggiore espressione di CD80, HLAABCm, HLAABCr; HLADRm e HLADRr; dove HLAABCm e HLADRm rappresentano l'intensità media della fluorescenza per cellula, mentre HLAABCr e HLADRr rappresentano la percentuale di cellule che superano il gate e sono quindi catalogate come positive. L’espressione di MCHC aumenta nei pazienti trapiantati rispetto ai non trapiantati in quanto il rene trapiantato sta esprimendo antigeni in modo non tollerigeno in quanto organo non self, la terapia immunosoppressiva determina un’inibizione del linfociti T a valle del CD80, impedendo il rigetto. Conclusioni- La diagnosi delle neoplasie renali che viene effettuata nell’ambito di programma di follow-up nel paziente trapiantato di rene e di screening nel paziente uremico consente di individuare neoplasie in stadio precoce, migliorandone l’outcome e riducendo la necessità di terapie adiuvanti. Sembra esserci un’attivazione nel processo di immunosorveglianza suggerito dall’ elevata espressione della molecola di costimolazione CD80 nei pazienti affetti da neoplasie renali. Rimane da chiarire il ruolo della terapia immunosoppressiva nell’immunosorveglianza.
APA, Harvard, Vancouver, ISO, and other styles
8

Rashidkhani, Bahram. "Diet and renal cell carcinoma /." Stockholm, 2005. http://diss.kib.ki.se/2005/91-7140-163-6/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Fallah, Abdul Karim. "Genomic studies in renal cell carcinoma." Thesis, Manchester Metropolitan University, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.528380.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Al-Sharhan, Mouza Abdulla. "Prognostic factors in renal cell carcinoma." Thesis, University of Newcastle Upon Tyne, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.285788.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Carcinomi renali"

1

Bukowski, Ronald M., and Andrew Novick. Renal Cell Carcinoma. New Jersey: Humana Press, 2000. http://dx.doi.org/10.1385/1592592295.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Campbell, Steven C., and Brian I. Rini, eds. Renal Cell Carcinoma. Totowa, NJ: Humana Press, 2013. http://dx.doi.org/10.1007/978-1-62703-062-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bukowski, Ronald M., Robert A. Figlin, and Robert J. Motzer, eds. Renal Cell Carcinoma. New York, NY: Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4939-1622-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bukowski, Ronald M., Robert A. Figlin, and Robert J. Motzer, eds. Renal Cell Carcinoma. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-332-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Oya, Mototsugu, ed. Renal Cell Carcinoma. Tokyo: Springer Japan, 2017. http://dx.doi.org/10.1007/978-4-431-55531-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Figlin, Robert A., W. Kimryn Rathmell, and Brian I. Rini, eds. Renal Cell Carcinoma. Boston, MA: Springer US, 2012. http://dx.doi.org/10.1007/978-1-4614-2400-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Renal cell carcinoma. Shelton, Conn: People's Medical Pub. House, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Debruyne, Frans M. J., Ronald M. Bukowski, J. Edson Pontes, and Pieter H. M. de Mulder, eds. Immunotherapy of Renal Cell Carcinoma. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-75853-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bukowski, Ronald M., James H. Finke, and Eric A. Klein. Biology of Renal Cell Carcinoma. New York, NY: Springer New York, 1995. http://dx.doi.org/10.1007/978-1-4612-2536-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

M, Bukowski Ronald, Finke James H. 1944-, and Klein Eric A. 1955-, eds. Biology of renal cell carcinoma. New York: Springer-Verlag, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Carcinomi renali"

1

Bukowski, Ronald M., Robert A. Figlin, and Robert J. Motzer. "Targeted Therapy for Metastatic Renal Cell Carcinoma: Overview." In Renal Cell Carcinoma, 1–12. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-332-5_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rini, Brian I. "Additional Tyrosine Kinase Inhibitors in Renal Cell Carcinoma." In Renal Cell Carcinoma, 189–93. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-332-5_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ramakrishnan, Vanitha, Vinay Bhaskar, Melvin Fox, Keith Wilson, John C. Cheville, and Barbara A. Finck. "Integrin α5β1 as a Novel Therapeutic Target in Renal Cancer." In Renal Cell Carcinoma, 195–209. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-332-5_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Shuch, Brian, Arie S. Belldegrun, and Robert A. Figlin. "Carbonic Anhydrase IX: Biology and Clinical Approaches." In Renal Cell Carcinoma, 211–29. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-332-5_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Oosterwijk-Wakka, J. C., Otto C. Boerman, Peter F. A. Mulders, and Egbert Oosterwijk. "Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma: Biological and Clinical Studies." In Renal Cell Carcinoma, 231–47. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-332-5_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Reckamp, Karen L., Robert A. Figlin, and Robert M. Strieter. "Chemokines in Renal Cell Carcinoma: Implications for Tumor Angiogenesis and Metastasis." In Renal Cell Carcinoma, 249–65. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-332-5_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Cho, Daniel, James W. Mier, and Micheal B. Atkins. "PI3K/Akt/mTOR Pathway: A Growth and Proliferation Pathway." In Renal Cell Carcinoma, 267–85. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-332-5_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Jonasch, Eric, and Cheryl Lyn Walker. "EGFR and HER2: Relevance in Renal Cell Carcinoma." In Renal Cell Carcinoma, 287–303. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-332-5_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Peruzzi, Benedetta, Jean-Baptiste Lattouf, and Donald P. Bottaro. "The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma." In Renal Cell Carcinoma, 321–34. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-332-5_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Mizutani, Yoichi, Akihiro Kawauchi, Benjamin Bonavida, and Tsuneharu Miki. "Smac/DIABLO: A Proapoptotic Molecular Target in Renal Cell Cancer." In Renal Cell Carcinoma, 335–46. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-332-5_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Carcinomi renali"

1

Valdameri, Joana Scapinello, Anna Carolina Flumignan Bucharles, Caroline Baldasso Vieira, Thainá Mirella Macedo, and Maria Luiza Lyczacovski Riesemberg. "CLASSIFICAÇÃO E CARACTERÍSTICAS HISTOLÓGICA DOS CARCINOMAS DE CÉLULAS RENAIS MAIS FREQUENTES." In I Congresso On-line Nacional de Histologia e Embriologia Humana. Revista Multidisciplinar em Saúde, 2022. http://dx.doi.org/10.51161/rems/3214.

Full text
Abstract:
Introdução: O carcinoma de células renais (CCR), tumor frequente na população, é caracterizado pelo aumento de massa no parênquima renal, onde encontram-se as unidades funcionais do rim. Sua nova classificação, publicada em 2016 pela WHO (World Health Organization), é baseada em aspectos histológicos que variam conforme os subtipos. Objetivos: Identificar histopatologicamente os principais subtipos de carcinomas de células renais, evidenciando melhor decisão de terapia para melhor prognóstico. Material e métodos: A metodologia consistiu em uma revisão literária de artigos publicados em língua inglesa ou portuguesa, nas bases de dados “Pubmed” e "Scielo", no período entre 2018 e 2022. Foram utilizados como descritores “carcinoma real” e “histologia de carcinoma", e feito leitura dos artigos de maior relevância, considerando cronologia e local de publicação. Resultados: Por meio da análise dos artigos, foi evidenciado que o CCR está entre os tumores mais frequentes na população, sendo os subtipos mais recorrentes os carcinomas renais das células claras (CCRcc), seguidos pelos tipos papilíferos (CCRp) e cromófobos (CCRc). Sua classificação baseia-se em aspectos histológicos, e sua nomenclatura está associada ao citoplasma típico de células tumorais, bem como características estruturais e morfológicas. O CCRcc, que corresponde entre 65 e 70% dos casos, apresenta prognóstico desfavorável. Possui origem no epitélio do túbulo contorcido proximal e é caracterizado pela presença de células claras devido ao citoplasma eosinofílico rico em lipídios e glicogênio. O CCRp, de origem histológica no néfron distal e epitélio tubular, se caracteriza por um tumor imperceptível à palpação, e é dividido em dois subtipos, um com citoplasma escasso e outro com citoplasma eosinofílico. Por fim, o CCRc se origina de células intercalares dos ductos coletores, sendo menos agressivo e mais comum após 60 anos representa 5% dos CCR, possui prognóstico favorável, com baixa incidência de metástase. Existem, ainda, outros subtipos, porém são menos frequentes em relação aos expostos anteriormente. Conclusão: Diante do exposto, nota-se a importância da classificação histológica dos CCR, facilitando a compreensão da função e da composição dos tecidos lesionados, com o objetivo de realizar o prognóstico e tratamento adequado.
APA, Harvard, Vancouver, ISO, and other styles
2

López, Alejandro, Sofía Parejo, Juan Ángel González, Jesús Donate, Diego Rojo, Álvaro de la Serna, Irene González, María Rosa Meléndez, Enrique Vázquez, and Agustín Albillos. "Metástasis gástrica de carcinoma renal." In 43 Congreso de la Sociedad Española de Endoscopia Digestiva. Grupo Pacífico, 2021. http://dx.doi.org/10.48158/seed2021.p250.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ramakrishnan, Swathi, Paula Sotomayor, Kristin Lehet, and Roberto Pili. "Abstract 5016: Epigenetics in renal cell carcinoma." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-5016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Saleem, M. D. "Mediastinal Presentation of Renal Papilalry Cell Carcinoma." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a6963.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Oliveira, Marcos, Jorge Dionísio, Ambrus Szantho, and Duro Da Costa. "Hemorrhagic Endobronchial metastasis of renal cell carcinoma." In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.2841.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Rocha, Jessica, George dos Passos, Luciano Filho, Vitor Pereira, Paulo Sablewski, and Koji Tanaka. "Metastases intraventriculares de carcinoma renal de celulas claras." In XXXII Congresso Brasileiro de Neurocirurgia. Thieme Revinter Publicações Ltda, 2018. http://dx.doi.org/10.1055/s-0038-1672827.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ao, Bin, Rong Liu, Xin Wu, Qing Wen, Kuan Li, and Jianping Yin. "Segmentation of renal cell carcinoma using stain normalization." In 2022 2nd International Conference on Consumer Electronics and Computer Engineering (ICCECE). IEEE, 2022. http://dx.doi.org/10.1109/iccece54139.2022.9712719.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Wang, Lin, Paul Park, Huina Zhang, Frank La Marca, and Chia-Ying Lin. "Abstract 293: Characterization of renal tumor-initiating cells in human renal carcinoma cell lines." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-293.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Medalla, R., and J. Luna. "356 Papillary squamous carcinoma of the cervix with metachronous clear cell renal cell carcinoma." In IGCS 2020 Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2020. http://dx.doi.org/10.1136/ijgc-2020-igcs.306.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Munusamy, Shankar, Akila Gopalakrishnan, Sreenithya Ravindran, Feras Alali, and Ali H. Eid. "Anti-Neoplastic Effects of Annonacin against Renal Cell Carcinoma." In Qatar Foundation Annual Research Conference Proceedings. Hamad bin Khalifa University Press (HBKU Press), 2016. http://dx.doi.org/10.5339/qfarc.2016.hbpp3364.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Carcinomi renali"

1

Ismail, Mohamed, Monish Aron, Joe Philip, and Faris Abushamma. Renal cell carcinoma – minimally invasive nephron sparing surgery. BJUI Knowledge, January 2022. http://dx.doi.org/10.18591/bjuik.0114.v2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Schmidt, Laura S., and W. Marston Linehan. Principles and management of hereditary renal cell carcinoma. BJUI Knowledge, March 2022. http://dx.doi.org/10.18591/bjuik.0095.v2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Drake, Richard R., and Alexander Parker. Tissue and Metabolomic Biomarkers of Recurrent Renal Cell Carcinoma. Fort Belvoir, VA: Defense Technical Information Center, April 2013. http://dx.doi.org/10.21236/ada592797.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Spinassé Dettogni, Raquel, Elaine Stur, Lauziene Andrade Soares, Diego do Prado Ventorim, Raquel Silva Reis, Fernanda Mariano Garcia, and Iúri Drumond Louro. Variação Patogênica no Gene RAD51C no Carcinoma Renal de Células Claras. Buenos Aires: siicsalud.com, April 2019. http://dx.doi.org/10.21840/siic/159359.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Stroman, Luke, and Tim O'Brien. Management of renal cell carcinoma with inferior vena cava (IVC) involvement. BJUI Knowledge, January 2022. http://dx.doi.org/10.18591/bjuik.0738.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Stewart, B. J. Mass Spectrometry Data Set for Renal Cell Carcinoma and Polycystic Kidney Disease Cell Models. Office of Scientific and Technical Information (OSTI), January 2017. http://dx.doi.org/10.2172/1342001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Zhou, Xiao, and Guangcheng Luo. A meta-analysis of platelet-lymphocyte ratio: a merit attention prognostic factor in renal cell carcinoma. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2021. http://dx.doi.org/10.37766/inplasy2021.9.0064.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Chen, Cheng-Che, and Hao-En Lin. Survival Benefits and Bleeding Risk of Anti-VEGF Agents for Renal Cell Carcinoma (RCC): A Updated Systematic Review and Meta-Analysis of Phase 2 and 3 Randomized Clinical Trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2023. http://dx.doi.org/10.37766/inplasy2023.3.0007.

Full text
Abstract:
Review question / Objective: To investigate the survival benefits (PFS, DFS, OS) and bleeding risk of the anti-VEGF agents compared with placebo or interferon alpha (IFNa) in patients with RCC. Condition being studied: Part 1. The hazard ratio (HR) of the progression-free survival (PFS) and overall survival (OS) of anti-VEGF agents vs. non/placebo for patients with unresectable, advanced, metastatic, renal cell carcinoma (RCC). Part 2. The HR of the disease-free survival (PFS) and OS of anti-VEGF agents vs. non/placebo for patients with post-nephrectomy RCC (adjuvant use). Part 3. The HR of the PFS and OS of anti-VEGF agents vs. IFN-alpha for patients with RCC. Part 4. The relative risk (RR) of bleeding events of anti-VEGF agents vs. placebo or IFN-alpha for patients with RCC.
APA, Harvard, Vancouver, ISO, and other styles
9

Zhou, Xiao, and Guangcheng Luo. Whether the consistency of tumor thrombus has prognostic significance in patients with renal cell carcinoma—a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, February 2022. http://dx.doi.org/10.37766/inplasy2022.2.0015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Jin, Hongyu, and Man Zhang. Adjuvant targeted therapy combined with surgery for advanced and metastatic renal cell carcinoma: Protocol for a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2020. http://dx.doi.org/10.37766/inplasy2020.11.0093.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Carcinomi renali' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography